ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-OR034

Bridging Gaps in Kidney Care: A Pilot Trial of ImPart-Multi for Black Patients with CKD and Comorbidities

Session Information

Category: Diversity and Equity in Kidney Health

  • 900 Diversity and Equity in Kidney Health

Authors

  • Gazaway, Shena, The University of Alabama at Birmingham School of Nursing, Birmingham, Alabama, United States
  • Gutierrez, Orlando M., The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
  • Wells, Rachel D, The University of Alabama at Birmingham School of Nursing, Birmingham, Alabama, United States
  • Lyas, Clare Nichols, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
  • Cole, Alicia S., The University of Alabama at Birmingham School of Nursing, Birmingham, Alabama, United States
  • Martinez, Isaac, The University of Alabama at Birmingham School of Nursing, Birmingham, Alabama, United States
  • Nix Parker, Tamara M., The University of Alabama at Birmingham School of Nursing, Birmingham, Alabama, United States
  • Armstrong, Margaret, The University of Alabama at Birmingham School of Nursing, Birmingham, Alabama, United States
  • Dionne-Odom, James N., The University of Alabama at Birmingham School of Nursing, Birmingham, Alabama, United States
Background

In the concurrent management of chronic kidney disease (CKD) and chronic metabolic conditions (such as hypertension [HTN] or diabetes), it has been found that Black patients remain unaware of their advancing kidney illness risks. We developed ImPart-Multi (Improving Decision Partnership) for these high-risk individuals to improve their ability to engage in health-related decision-making.

Methods

Utilizing a community-engaged approach, a pilot randomized trial assessed ImPart-Multi's feasibility, acceptability, and preliminary efficacy in stage 3B/4 CKD patients with concurrent diagnosis of HTN or diabetes and their care partners. From 10/2023 - 10/2024, dyads were randomized into four groups: basic communication skills, social support effectiveness, combination, and wait-listed. Care partners did not receive sessions but completed data collection only. Outcomes (Decision Conflict Scale, Social Support Effectiveness Scale, Dyadic Coping Inventory, KDQOL-36, Hospital Anxiety and Distress Scale, and the PROMIS-10) were collected at baseline and 12 weeks. Paired sample t-tests were conducted to detect differences. Acceptability interviews were conducted and analyzed.

Results

11 dyads (22 participants) were randomized. Regarding feasibility, 73% completed assigned activities, including data collection. Mean scores for decision conflict decreased, indicating improved perception of conflict when making decisions, and dyadic coping means improved, indicating improved coping. These findings were not statistically significant (see figure 1). ImPart-MULTI was described as informative, helpful, and an intervention that could be useful for others.

Conclusion

Results demonstrate that implementing ImPart-Multi is feasible and acceptable, potentially decreasing decision conflict and improving dyadic coping. These findings and feedback from our community advisory board will help us refine ImPart-Multi for a fully powered R01 optimization trial.

Funding

  • Other NIH Support

Digital Object Identifier (DOI)